{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967360",
  "id": "02967360",
  "pages": 9,
  "price_sensitive": false,
  "date": "20250708",
  "time": "1435",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06llq02r2g29fp.pdf",
  "summary": "- **Director Securities Issuance**:  \n  - Performance Rights issued in lieu of fees (priced at $0.040, based on 30-day VWAP):  \n    - Sean Williams: 1,074,866 Rights ($42,732 value)  \n    - Dr Ron Wise: 746,736 Rights ($29,687 value)  \n    - Anthony Fitzgerald: 503,324 Rights ($20,010 value)  \n  - Unlisted Options issued (3-year term):  \n    - Dr Ron Wise: 500,000  \n    - Anthony Fitzgerald: 500,000  \n\n- **Background Context**:  \n  - Company holds $38.5m funding facility for clinical trials (IRX-211 for cancer pain, IRX-616a for panic disorder).  \n\n**Note**: No material trading or capital markets impact identified beyond director remuneration restructuring.",
  "usage": {
    "prompt_tokens": 3649,
    "completion_tokens": 180,
    "total_tokens": 3829,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T04:40:45.115231"
}